摘要
目的评价SPECT/CT同机融合显像对SPECT难于确诊骨病灶的诊断价值。方法对SPECT难于确诊的35例肿瘤患者的37个病灶行SPECT/CT同机融合显像。由2名经过放射学培训的核医学科医师盲法独立阅片。所有病灶均以病理、磁共振结果或6个月以上的随诊为最终诊断结果。结果SPECT±CT和SPECT/CT分别可对17个（17/ 37,45.95%）和30个（30/37,81.08%）病灶做出准确诊断,SPECT/CT诊断的正确率较SPECT明显提高（χ^2=9.855,P= 0.002）。SPECT、SPECT＋CT和SPECT/CT诊断为性质待定的病灶,经随访确诊后恶性病灶所占比率分别为29.7%（11/ 37）、26.3%（5/19）和16.7%（1/6）。结论SPECT/CT同机融合显像有助于鉴别诊断SPECT难于确诊骨病灶的性质,应作为SPECT显像的重要补充。
Objective To evaluate radionuclide bone SPECT/CT fusion imaging in the assessment of foci bone metabolism classified as indeterminate on SPECT. Methods A total of 37 lesions in 35 patients without concrete diagnosis on SPECT underwent radionuclide bone SPECT/CT imaging. The final diagnosis of these patients were obtained with MRI, pathology or follow-up for more than six months. Results Among 37 equivocal lesions on bone SPECT, the diagnostic accuracy was 45. 95% （17/37） for SPECT＋CT and 81.08% （30/37） for SPECT/CT, respectively （χ^2 =9. 855, P=0. 002）. Of the equivocal lesions by SPECT, SPECT＋CT and SPECT/CT, the ratio of malignancy was 29.7% （11/37）, 26. 3% （5/19） and 16.7% （1/6）, respectively. Conclusion Radionuclide bone SPECT/CT fusion imaging is of great importance in the assessment of foci bone metabolism classified as indeterminate on bone SPECT, and should be used as a valuable supplementary procedure to hone SPECT.
出处
《中国医学影像技术》
CSCD
北大核心
2008年第10期1641-1643,共3页
Chinese Journal of Medical Imaging Technology
